



## **Aerpio Announces Presentations on Novel Treatments for Glaucoma and Retinal Diseases at ARVO 2018 Annual Meeting**

May 4, 2018

CINCINNATI--(BUSINESS WIRE)--May 4, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, presented new preclinical and clinical results for several of its development programs at the [Association for Research in Vision and Ophthalmology \(ARVO\) 2018 annual meeting](#) in Honolulu, HI this week. The three presentations are listed below:

- Subcutaneous Administration of AKB-9778, a Tie2 Activator, Reduces IOP in Patients with Diabetic Retinopathy. Abstract Number: 1252 - A0093 Presenter: Mitch Brigell, PhD
- Topical or Subcutaneous Administration of AKB-9778, a Tie2 Activator, Reduces IOP in NZW Rabbits. Abstract Number: 2719 - B0040. Presenter: Glenwood Gum, PhD
- A VE-PTP Antibody Activates Tie2 and Suppresses VEGF-Induced Retinal Vascular Leakage. Abstract Number: 199 - C0010. Presenter: Kevin Peters, MD

Kevin Peters, MD, Aerpio's Chief Scientific Officer, said, "There is a growing body of evidence supporting the importance of the Tie2 pathway in maintenance of the conventional outflow track for aqueous humor drainage from the eye. These considerations, combined with the results presented at ARVO, support the evaluation of topical AKB-9778 in open-angle glaucoma, and we are on track to advance this program into IND-enabling preclinical studies this year."

### **About Aerpio Pharmaceuticals**

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The Company's lead compound, AKB-9778, is a small molecule activator of the Tie2 pathway and is in clinical development for the treatment of non-proliferative diabetic retinopathy. For more information please visit [www.aerpio.com](http://www.aerpio.com).

### **About AKB-9778**

AKB-9778 is being developed as a subcutaneous injection for the treatment of non-proliferative diabetic retinopathy and as topical drops for the treatment of primary open-angle glaucoma. AKB-9778 binds to and inhibits vascular endothelial protein tyrosine phosphatase (VE-PTP), an important negative regulator of Tie2. Decreased Tie2 activity causes vascular instability in many diseases including diabetes. AKB-9778 activates the Tie2 receptor irrespective of extracellular levels of its binding ligands, angiotensin-1 (agonist) or angiotensin-2 (antagonist), and may be the most efficient pharmacologic approach to maintain normal Tie2 activation.

### **About ARP-1536**

ARP-1536, is a humanized monoclonal antibody that inhibits VE-PTP by binding the extracellular domain of VE-PTP. We are evaluating development options for ARP-1536, including once-monthly subcutaneous injection for the treatment of diabetic vascular complications and intravitreal injection for the treatment of advanced diabetic eye disease such as DME or PDR.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180504005590/en/>

Source: Aerpio Pharmaceuticals, Inc.

Investor:

Aerpio Pharmaceuticals, Inc.  
Michael Rogers, 513-985-1958  
Chief Financial Officer  
[mrogers@aerpio.com](mailto:mrogers@aerpio.com)